Zobrazeno 1 - 10
of 711
pro vyhledávání: ''
Autor:
Shahrooz Eshaghian, James R. Berenson, Gary T. Schwartz, Stephen Lim, Robert Vescio, Benjamin Eades, Tanya M. Spektor, Matthew Ghermezi, David Yashar, Daisy Martinez, Regina A. Swift
Publikováno v:
Leukemia & Lymphoma. 63:975-983
High-risk multiple myeloma (MM) continues to have a poor prognosis and remains a therapeutic challenge. This phase 2 study evaluated the efficacy and safety of elotuzumab in combination with pomalidomide, carfilzomib, and low-dose dexamethasone for p
Autor:
Raphael Clynes, Asher Chanan-Khan, Victoria R. Alegria, Ricardo D. Parrondo, Chelsea M. Johnson, Aneel Paulus, David M. Menke, Liuyan Jiang, Vivek Roy, Sikander Ailawadhi, David Liebowitz
Publikováno v:
Leukemia & Lymphoma. 63:738-742
Waldenstrom macroglobulinemia (WM) is an indolent, IgM-producing lymphoproliferative disorder that represents 1–2% of all non-Hodgkin lymphomas (NHL) [1]. High-risk patients, as defined by the inte...
Publikováno v:
Leukemia & Lymphoma. 63:946-954
To evaluate the cost-effectiveness of ponatinib compared with second-line TKIs in the treatment of adult patients with CML who failed, or were intolerant to, first-line TKIs. A Markov state transition model was conducted. Model transition, adverse-ef
Autor:
Georgios Dryllis, Elena E. Solomou, Andreas Giannopoulos, Nefeli Giannakopoulou, Panayiotis Panayiotidis, Sevastianos Hatzidavid, Nora-Athina Viniou, Vasiliki Pappa, Theodoros Loupis, Christina-Nefeli Kontandreopoulou, Ioannis Kotsianidis, Katerina Zoi, Athanasios Galanopoulos, Maria Dimou, Argiris Symeonidis, Panagiotis T. Diamantopoulos
Publikováno v:
Leukemia & Lymphoma. 63:729-737
Ribonucleotide Reductase (RNR) is a two-subunit (RRM1, RRM2) enzyme, responsible for the conversion of ribonucleotides to deoxyribonucleotides required for DNA replication. To evaluate RNR as a biomarker of response to 5-azacytidine, we measured RNR
Autor:
Alicia Enrico, Viktor Komlosi, Mary Ann Anderson, Kavita Sail, Ewa Lech-Marańda, Madhavi Pai, Shang-Ju Wu, Tara Cochrane, Tadeusz Robak, Robert Weinkove, Nikitin Ea, Evgueniy Hadjiev, John Pesko, David Gómez-Almaguer, Tamás Masszi
Publikováno v:
Leukemia & Lymphoma. 63:304-314
Venetoclax, a potent B-cell lymphoma-2 (BCL-2) inhibitor, has demonstrated clinical efficacy in chronic lymphocytic leukemia (CLL). VENICE II is an open-label, single-arm, phase 3b study (NCT02980731) evaluating the impact of venetoclax monotherapy (
Autor:
Marina Konopleva, Koichi Takahashi, Nicholas J. Short, Courtney D. DiNardo, Caitlin R. Rausch, Sanam Loghavi, Sangeetha Venugopal, Naval Daver, Yesid Alvarado, Musa Yilmaz, Maro Ohanian, Hagop M. Kantarjian, Abhishek Maiti, Jing Ning, Wei Qiao, Tapan M. Kadia, Farhad Ravandi, Koji Sasaki
Publikováno v:
Leukemia & Lymphoma. 62:3501-3505
Acute myeloid leukemia (AML) is heterogenous in its pathogenesis as well as outcomes, which in turn is influenced by patient- and disease-related factors including age, ability to tolerate treatmen...
Autor:
Andrew E. Whiteley, Andrew S. Murray, Trevor T. Price, Prioty Islam, Brennan G. Simon, Maegan L. Brockman, Hisayuki Yao, Dorothy A. Sipkins, Sarah M. Ridge
Publikováno v:
Leuk Lymphoma
The majority of adult patients with acute lymphoblastic leukemia (ALL) suffer relapse, and in patients with central nervous system (CNS) metastasis, prognosis is particularly poor. We recently demonstrated a novel route of ALL CNS metastasis dependen
Autor:
Man Qiao, Chao-Ling Wan, Shengli Xue, Jing-Ying Zou, Xiang-Dong Shen, Song-Bai Liu, Qiao-cheng Qiu, Jia Yin
Publikováno v:
Leukemia & Lymphoma. 62:3300-3303
T-cell acute lymphoblastic leukemia (T-ALL) is a heterogeneous hematologic disease characterized by immature lymphoid cell proliferation in the bone marrow, peripheral blood and other organs [1]. C...
Autor:
Moshe Yeshurun, Ronit Gurion, Ofir Wolach, Gilad Itchaki, Tamar Berger, Shai Shimony, Meir Lahav, Einat Bar-Sever, Pia Raanani
Publikováno v:
Leukemia & Lymphoma. 62:2921-2927
Late onset neutropenia (LON) after rituximab is a previously described complication. We aimed to assess and characterize LON after obinutuzumab, a novel anti-CD20 antibody, in the real-world setting and compare it to LON after rituximab therapy. We r
Autor:
Anita Zahlten-Kumeli, Katja Weisel, Xavier Leleu, David S. Siegel, Bifeng Ding, Rohan Medhekar
Publikováno v:
Leukemia & Lymphoma. 62:3002-3010
CANDOR (NCT03158688) compared carfilzomib, dexamethasone, and daratumumab (KdD) to carfilzomib and dexamethasone (Kd) in patients with relapsed/refractory multiple myeloma (RRMM). A secondary objective of CANDOR was to evaluate health-related quality